Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease

References

• Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain. 2020;143(10):3077–3088. doi:10.1093/brain/awaa238
   PubMed Web of Science ®Google Scholar
• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3(1):17013. doi:10.1038/nrdp.2017.13
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat Disord. 2020;80(Suppl 1):S7–S12. doi:10.1016/j.parkreldis.2020.09.024
   PubMed Web of Science ®Google Scholar
• Titova N, Simon CP, Ray JGLK, Chaudhuri KR. Parkinson’s: a syndrome rather than a disease? J Neural Transm. 2017;124(8):907–914. doi:10.1007/s00702-016-1667-6
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649. doi:10.1002/mds.22643
   PubMed Web of Science ®Google Scholar
• Bock MA, Brown EG, Zhang L, Tanner C. Association of motor and nonmotor symptoms with health-related quality of life in a large online cohort of people with Parkinson disease. Neurology. 2022;98(22):E2194–E2203. doi:10.1212/WNL.0000000000200113
   PubMed Web of Science ®Google Scholar
• Santos-García D, Mir P, Cubo E, et al. COPPADIS-2015 (COhort of Patients with Parkinson’s disease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol. 2016;16(1):1–14. doi:10.1186/s12883-016-0548-9
   PubMedGoogle Scholar
• Alborghetti M, Bianchini E, Carolis L, De Galli S, Pontieri FE, Rinaldi D. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res. 2024;19(1):16–21. doi:10.4103/1673-5374.375299
   PubMed Web of Science ®Google Scholar
• Teixeira FG, Gago MF, Marques P, et al. Safinamide: a new hope for Parkinson’s disease? Drug Discov Today. 2018;23(3):736–744. doi:10.1016/j.drudis.2018.01.033
   PubMed Web of Science ®Google Scholar
• Stocchi F, Torti M. Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide. Drug Des Devel Ther. 2016;10:609–618. doi:10.2147/DDDT.S77749
   PubMed Web of Science ®Google Scholar
• Jamshidi N, Dawson A. The hot patient: acute drug-induced hyperthermia. Aust Prescr. 2019;42(1):24–28. doi:10.18773/austprescr.2019.006
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-esteban JC. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial 1. J Parkinsons Dis. 2021;11(1):187–198. doi:10.3233/JPD-202224
   PubMedGoogle Scholar
• Martí-Andrés G, Jiménez-Bolaños R, Arbelo-González JM, et al. Safinamide in clinical practice: a Spanish multicenter cohort study. Brain Sci. 2019;9(10):1–11. doi:10.3390/brainsci9100272
   Web of Science ®Google Scholar
• Abdelalem Aziz Ahmed M. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson’s disease. F1000Research. 2019;8:2078. doi:10.12688/f1000research.21372.1
   PubMedGoogle Scholar
• Schapira AHV, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 2017;74(2):216–224. doi:10.1001/jamaneurol.2016.4467
   PubMed Web of Science ®Google Scholar
• De Micco R, Satolli S, Siciliano M, et al. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurol Sci. 2022;43(1):357–364. doi:10.1007/s10072-021-05324-w
   PubMed Web of Science ®Google Scholar
• Cova I, Di Battista ME, Vanacore N, et al. Validation of the Italian version of the non motor symptoms scale for Parkinson’s disease. Park Relat Disord. 2017;34:38–42. doi:10.1016/j.parkreldis.2016.10.020
   PubMed Web of Science ®Google Scholar
• De Masi C, Liguori C, Spanetta M, et al. Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study. J Neural Transm. 2022;129(11):1331–1338. doi:10.1007/s00702-022-02538-w
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Barone P, Lopiano L, Stocchi F. The current evidence for the use of safinamide for the treatment of Parkinson’s disease. Drug Des Devel Ther. 2021;15:2507–2517. doi:10.2147/DDDT.S302673
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Jost WH, Bonizzoni E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson’s disease patients. J Parkinsons Dis. 2020;10(1):89–97. doi:10.3233/JPD-191765
   PubMedGoogle Scholar
• Hagell P, Nilsson MH. The 39-item Parkinson’s Disease Questionnaire (PDQ-39): is it a unidimensional construct ? Ther Adv Neurol Disord. 2009;2(4):205–214. doi:10.1177/1756285609103726
   PubMedGoogle Scholar
• Giossi R, Carrara F, Mazzari M, et al. Overall efficacy and safety of safinamide in Parkinson’s disease: a systematic review and a meta-analysis. Clin Drug Investig. 2021;41(4):321–339. doi:10.1007/s40261-021-01011-y
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–237. doi:10.1002/mds.25751
   PubMed Web of Science ®Google Scholar
• Maillet A, Krack P, Pelissier P, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016;139(9):2486–2502. doi:10.1093/aww190
   PubMedGoogle Scholar
• Weintraub D, Hauser RA, Elm JJ, et al. Rasagiline for mild cognitive impairment in Parkinson’s disease: a placebo-controlled trial. Mov Disorders. 2016;31(5):709–714. doi:10.1002/mds.26617
   PubMed Web of Science ®Google Scholar
• Sharaf J, Williams KAD, Tariq M, et al. The efficacy of safinamide in the management of Parkinson’s disease: a systematic review. Cureus. 2022;14(9). doi:10.7759/cureus.29118
   Web of Science ®Google Scholar
• Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C. Long-term effects of safinamide on mood fluctuations in Parkinson’s disease. J Parkinsons Dis. 2017;7(4):629–634. doi:10.3233/JPD-171143
   PubMedGoogle Scholar
• Hattori N, Kogo Y, Koebis M, et al. The effects of safinamide adjunct therapy on depression and apathy in patients with Parkinson’s Disease: post-hoc Analysis of a Japanese Phase 2/3 Study. Front Neurol. 2022;12. doi:10.3389/fneur.2021.752632
   PubMed Web of Science ®Google Scholar
• Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled, phase II/III study. Park Relat Disord. 2020;75:17–23. doi:10.1016/j.parkreldis.2020.04.012
   PubMed Web of Science ®Google Scholar
• Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73(4):273 LP- 278. doi:10.1212/WNL.0b013e3181ab2b58
   Web of Science ®Google Scholar
• Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660–665. doi:10.1016/j.parkreldis.2013.02.018
   PubMed Web of Science ®Google Scholar
• Blair HA, Dhillon S. Safinamide: a review in Parkinson’s disease. CNS Drugs. 2017;31(2):169–176. doi:10.1007/s40263-017-0408-1
   PubMed Web of Science ®Google Scholar
• Stocchi F, Antonini A, Berg D, et al. Safinamide in the treatment pathway of Parkinson’s disease: a European Delphi Consensus. Npj Park Dis. 2022;8(1). doi:10.1038/s41531-022-00277-z
   PubMed Web of Science ®Google Scholar
• Geroin C, Di Vico IA, Squintani G, Segatti A, Bovi T, Tinazzi M. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm. 2020;127(8):1143–1152. doi:10.1007/s00702-020-02218-7
   PubMed Web of Science ®Google Scholar
• Grigoriou S, Martínez-Martín P, Ray Chaudhuri K, et al. Effects of safinamide on pain in patients with fluctuating Parkinson’s disease. Brain Behav. 2021;11(10):1–9. doi:10.1002/brb3.2336
   Web of Science ®Google Scholar
• García DS, Guerra CL, Baña RY, et al. Safinamide improves non‐motor symptoms burden in Parkinson’s disease: an open‐label prospective study. Brain Sci. 2021;11(3):1–15. doi:10.3390/brainsci11030316
   Web of Science ®Google Scholar
• Siciliano M, Kluger B, De Micco R, et al. Validation of new diagnostic criteria for fatigue in patients with Parkinson disease. Eur J Neurol. 2022;29(9):2631–2638. doi:10.1111/ene.15411
   PubMed Web of Science ®Google Scholar
• Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010;133(11):3434–3443. doi:10.1093/brain/awq268
   PubMedGoogle Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415–423. doi:10.1016/S1474-4422(11)70073-4
   PubMed Web of Science ®Google Scholar
• Pauletti C, Locuratolo N, Mannarelli D, et al. Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide. J Neural Transm. 2023;130(7):915–923. doi:10.1007/s00702-023-02654-1
   PubMed Web of Science ®Google Scholar
• Qureshi AR, Rana AQ, Malik SH, et al. Comprehensive examination of therapies for pain in Parkinson’s disease: a systematic review and meta-analysis. Neuroendocrinology. 2018;51(3–4):190–206. doi:10.1159/000492221
   Google Scholar
• Neikrug AB, Maglione JE, Liu L, et al. Effects of sleep disorders on the non-motor symptoms of Parkinson disease. J Clin Sleep Med. 2013;9(11):1119–1129. doi:10.5664/jcsm.3148
   PubMed Web of Science ®Google Scholar
• Santos García D, Cabo López I, Labandeira Guerra C, et al. Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study. Neurol Sci. 2022;43(4):2537–2544. doi:10.1007/s10072-021-05607-2
   PubMed Web of Science ®Google Scholar
• Liguori C, Stefani A, Ruffini R, Mercuri NB, Pierantozzi M. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson’s disease patients: a validated questionnaires-controlled study. Park Relat Disord. 2018;57:80–81. doi:10.1016/j.parkreldis.2018.06.033
   PubMed Web of Science ®Google Scholar
• Batla A, Phé V, De Min L, Panicker JN. Nocturia in Parkinson’s disease: why does it occur and how to manage? Mov Disord Clin Pract. 2016;3(5):443–451. doi:10.1002/mdc3.12374
   PubMed Web of Science ®Google Scholar
• Jost WH. Urological problems in Parkinson’s disease: clinical aspects. J Neural Transm. 2013;120(4):587–591. doi:10.1007/s00702-012-0914-8
   PubMed Web of Science ®Google Scholar
• Gómez-López A, Sánchez-Sánchez A, Natera-Villalba E, et al. Surinpark: safinamide for urinary symptoms in Parkinson’s disease. Brain Sci. 2021;11(1):1–8. doi:10.3390/brainsci11010057
   Web of Science ®Google Scholar